PCA
VRTX icon

Pallas Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Pallas Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
2,200
+562
+34% +$249K 0.03% 332
2026
Q1 		$731K Sell
1,638
-2,603
-61% -$1.21M 0.03% 405
2025
Q4 		$1.92M Buy
4,241
+1,353
+47% +$583K 0.06% 229
2025
Q3 		$1.13M Sell
2,888
-171
-6% -$71.5K 0.04% 319
2025
Q2 		$1.36M Buy
3,059
+579
+23% +$267K 0.05% 261
2025
Q1 		$1.2M Buy
2,480
+19
+0.8% +$8.85K 0.05% 267
2024
Q4 		$991K Buy
2,461
+75
+3% +$34.8K 0.04% 234
2024
Q3 		$1.13M Sell
2,386
-5
-0.2% -$2.4K 0.05% 206
2024
Q2 		$1.17M Buy
2,391
+1,673
+233% +$726K 0.05% 195
2024
Q1 		$300K Buy
718
+128
+22% +$54.1K 0.01% 359
2023
Q4 		$240K Sell
590
-61
-9% -$22.5K 0.01% 336
2023
Q3 		$233K Buy
651
+14
+2% +$4.9K 0.01% 316
2023
Q2 		$228K Buy
+637
New +$215K 0.01% 242
2021
Q4 		– Sell
-1,247
Closed -$236K – 406
2021
Q3 		$236K Sell
1,247
-8,803
-88% -$1.72M 0.03% 340
2021
Q2 		$2.01M Buy
10,050
+1,657
+20% +$347K 0.28% 70
2021
Q1 		$1.79M Buy
+8,393
New +$1.84M 0.4% 52

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Pallas Capital Advisors's VRTX Position: Q2 2026 in Review

Pallas Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 34% in Q2 2026, buying an estimated $249K and bringing the position to 2,200 shares worth $1.09M. The position accounts for 0.03% of the portfolio, ranked #332.

Pallas Capital Advisors first reported a position in VRTX in Q1 2021 and has held it in 16 quarters since. The position peaked at $2.01M in Q2 2021. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Pallas Capital Advisors held 2,200 shares of Vertex Pharmaceuticals worth $1.09M as of Q2 2026.
  • Pallas Capital Advisors bought 562 Vertex Pharmaceuticals shares in Q2 2026, an estimated $249K.
  • Vertex Pharmaceuticals made up 0.03% of Pallas Capital Advisors's portfolio in Q2 2026, its #332 holding.
  • Pallas Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
  • Pallas Capital Advisors's Vertex Pharmaceuticals position peaked at $2.01M in Q2 2021.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.